The NIAID, part of the National Institute of Health, will lead the trial that will also evaluate the NIH vaccine’s safety and ability to stimulate an immune response in participants, and assess the optimal dose for administration.

Currently, there is no licensed vaccine to prevent disease caused by Zika infections, mainly transmitted via the bite of infected Aedes aegypti mosquitoes but also can be transmitted sexually.